Literature DB >> 479910

The significance of cerebral atrophy for the symptomatology of Parkinson's disease.

E Schneider, P A Fischer, P Jacobi, H Becker, H Hacker.   

Abstract

Hitherto published results on the impact of brain atrophy on the neurological and psychopathological sympion of this problem without risk of complications. We investigated 173 parkinsonian patients (89 men, 84 women) aged 37--83 years. Besides CT in all patients a standardized neurological and psychopathological investigation was carried out, including psychological tests, intelligence, personality structure, fine motor performance and visual reaction times. The investigations revealed pronounced correlations between CT-findings and more severe clinical symptomatology and a corresponding impairment in daily activities in the levodopa-treated and particularly in the untreated group, above all when there was a combination of cortical atrophy and ventricular enlargement. The same was true for fine motor performance and simple and complex reaction times. These functions were more impaired in patients with brain atrophy, irrespective of its localisation, whether cortical atrophy or ventricular enlargement. In contrast, no statistically significant relationship between the different parameters of brain atrophy and intelligence could be found. Considering cortical atrophy as a specific sign in Parkinson's disease -- our results are in favour of this assumption -- and ventricular enlargement more related to increasing age, parkinsonism is influenced by extranigral lesions inherent in the disease and dependent on increasing age.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479910     DOI: 10.1016/0022-510x(79)90050-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Cerebral atrophy and long-term response to levodopa in Parkinson's disease.

Authors:  E Schneider; P A Fischer; P Jacobi; H Becker; M Beyer
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

Review 2.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

3.  Cognitive and motor shifting aptitude disorder in Parkinson's disease.

Authors:  A R Cools; J H van den Bercken; M W Horstink; K P van Spaendonck; H J Berger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

4.  Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease.

Authors:  R G Brown; C D Marsden; N Quinn; M A Wyke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

5.  Magnetic resonance imaging in dementia of Parkinson's disease.

Authors:  S J Huber; E C Shuttleworth; J A Christy; D W Chakeres; A Curtin; G W Paulson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

6.  Cerebral atrophy in Parkinson's disease--represented in CT.

Authors:  H Becker; E Schneider; H Hacker; P A Fischer
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979-07-04

7.  The course of brain atrophy in Parkinson's disease.

Authors:  E Schneider; H Becker; P A Fischer; H Grau; P Jacobi; R Brinkmann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979-07-04

8.  Treatment of Parkinson's disease: problems with a progressing disease.

Authors:  U K Rinne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Features of brain atrophy in Parkinson's disease. A CT scan study.

Authors:  I Steiner; J M Gomori; E Melamed
Journal:  Neuroradiology       Date:  1985       Impact factor: 2.804

10.  Computed tomography brain changes in parkinsonian dementia.

Authors:  R Inzelberg; T Treves; I Reider; I Gerlenter; A D Korczyn
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.